SCHEMBL3900452

SCHEMBL3900452

COC(=O)C1=C(Nc2ccc(C)cc2)CC(C(=O)OC)C(Nc2ccc(C)cc2)C1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 11/20 0.45
▸ KDM4E B2RXH2 4/20 0.36
▸ LMNA P02545 3/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ NPSR1 Q6W5P4 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ MAPK1 P28482 2/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ GAA P10253 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3895790 0.89 ACHE (0.43) ACHESMN1; SMN2HPGDMEN1KMT2A
SCHEMBL3899768 0.89 ACHE (0.43) ACHESMN1; SMN2ALDH1A1MAPTHPGD
SCHEMBL3909908 0.89 ACHE (0.44) ACHEALDH1A1MAPTHPGDMAPK1
SCHEMBL3905199 0.87 SLC6A2 (0.41) ACHEKDM4ELMNASMN1; SMN2MAPT
SCHEMBL3902804 0.87 ALDH1A1 (0.36) ACHEKDM4ESMN1; SMN2ALDH1A1MAPT
SCHEMBL3899791 0.86 ACHE (0.39) ACHEKDM4EALDH1A1MAPTMAPK1
SCHEMBL3908430 0.86 ACHE (0.33) ACHELMNAMAPTMAPK1
SCHEMBL3897271 0.85 JAK3 (0.36) ACHESMN1; SMN2ALDH1A1HPGD
SCHEMBL28825748 0.76 HPGD (0.41) ACHEKDM4ELMNASMN1; SMN2ALDH1A1
SCHEMBL3911811 0.75 ACHE (0.47) ACHEKDM4ELMNAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0632106-B2 Process for the production of 2,5-di(arylamino)-3,6- dihydroterephthalic acid dialkyl ester, and process for the production of quinacridone from said ester as intermediate TOYO INK MFG CO (JP) 2009-02-25 — — EP disclosed
US-20090017307-A1 Process for the Preparation of Organic Materials MCA TECHNOLOGIES, GMBH (CH) 2009-01-15 — — US disclosed
US-20080060554-A1 Process for the Preparation of Organic Materials MCA TECHNOLOGIES, GMBH (CH) 2008-03-13 — — US disclosed
US-20070119345-A1 Process for the preparation of organic materials MCA TECHNOLOGIES, GMBH (CH) 2007-05-31 — — US disclosed
EP-1725619-A1 PROCESS FOR THE PREPARATION OF ORGANIC PIGMENTS MCA Technologies GMBH (CH) 2006-11-29 — — EP disclosed
WO-2005085364-A1 PROCESS FOR THE PREPARATION OF ORGANIC PIGMENTS MCA TECHNOLOGIES GMBH (CH) 2005-09-15 — — WO disclosed
EP-0632106-B1 Process for the production of 2,5-di(arylamino)-3,6- dihydroterephthalic acid dialkyl ester, and process for the production of quinacridone from said ester as intermediate TOYO INK MFG CO (JP) 2001-08-22 — — EP disclosed
EP-0654472-B1 Process for the production of 6,13-dihydroquinacridones TOYO INK MFG CO (JP) 2000-03-29 — — EP disclosed
US-5817817-A Process for the production of 2,5-di(arylamino)-3,6-dihydroterephthalic acid dialkyl ester, and process for the production of quinacridone from said ester as intermediate TOYO INK MANUFACTURING CO., LTD. (JP) 1998-10-06 — — US disclosed
US-5659036-A Process for the production of 2,5-di(arylamino)-3,6-dihydroterephthalic acid dialkyl ester, and process for the production of quinacridone from said ester as intermediate TOYO INK MANUFACTURING CO., LTD. (JP) 1997-08-19 — — US disclosed
US-5610306-A ALCOHOL ELIMINATION REACTION OF 2,5-DI(PHENYLAMINO)-3,6--DIHYDROTEREPHTHALIC ACID DIALKYL ESTER; CYCLIZATION TOYO INK MANUFACTURING CO., LTD. (JP) 1997-03-11 — — US disclosed
EP-0654472-A1 Process for the production of 6,13-dihydroquinacridones and apparatus for use for the production TOYO INK MANUFACTURING CO., LTD. (JP) 1995-05-24 — — EP disclosed
EP-0632106-A1 Process for the production of 2,5-di(arylamino)-3,6- dihydroterephthalic acid dialkyl ester, and process for the production of quinacridone from said ester as intermediate TOYO INK MANUFACTURING CO., LTD. (JP) 1995-01-04 — — EP disclosed
US-5367096-A Process for the preparation of 2,5-di(phenylamino)terephthalic acid and dialkyl esters thereof in high purity HOECHST AKTIENGESELLSCHAFT (DE) 1994-11-22 — — US disclosed
US-5093497-A PROCESS FOR THE PREPARATION OF A SUBSTITUTED OR UNSUBSTITUTED QUINACRIDONE BAYER AKTIENGESELLSCHAFT (DE) 1992-03-03 — — US disclosed
US-4758664-A Process for the preparation of linear quinacridones HOECHST AKTIENGESELLSCHAFT (DE) 1988-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090017307-A1 Process for the Preparation of Organic Materials KLK4, PDK4, GRK1 ACHE 2362/4885KDM4E 3091/4885LMNA 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback